ABI3BP

Across TCGA pan-cancer cohorts, ABI3BP Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ABI3BP data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ABI3BP Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ABI3BP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LIHC, and THYM are the cancer types where ABI3BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.966	0.595	<.001	36	view →
LIHC	OS	Median	All	0.128	0.783	.001	33	view →
THYM	OS	Median	All	0.186	0.931	<.001	15	view →
GBM	OS	Median	All	0.030	0.416	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ABI3BP–UCEC (DFS)

Open the UCEC breakdown →